1. Quinolones, fluoroquinolones to be discussed in EMA hearing

   News item 21 April 2018 Pages: 1 - 1

2. Sevoflurane: risk of bradycardia in Down syndrome children

   News item 21 April 2018 Pages: 2 - 2

3. ADE rate similar with low- and high-dose empagliflozin

   Clinical study 21 April 2018 Pages: 3 - 3

4. Artemisinin-based treatment in Uganda: adverse drug reactions

   Clinical study 21 April 2018 Pages: 4 - 4

5. Birth defects following pandemic influenza vaccination

   Clinical study 21 April 2018 Pages: 5 - 5

6. Certolizumab pegol: no teratogenic effect in pregnant women

   Clinical study 21 April 2018 Pages: 6 - 6

7. Insulin degludec reduces costs and risk of severe hypoglycaemia

   Clinical study 21 April 2018 Pages: 7 - 7

8. Lamotrigine not effective or cost effective in BPD

   Clinical study 21 April 2018 Pages: 8 - 8

9. Lithium toxicity: use of acute care services

   Clinical study 21 April 2018 Pages: 9 - 9

10. NSAIDs, paracetamol do not consistently cause IBD flare-ups?

    Review 21 April 2018 Pages: 10 - 10

11. Osteoporosis-related fractures with tenofovir disoproxil fumarate

    Clinical study 21 April 2018 Pages: 11 - 11

12. Postmarketing modifications to cancer drug labelling in US

    Non-clinical study 21 April 2018 Pages: 12 - 12

13. Testosterone cipionate/testosterone enanthate

    Case report 21 April 2018 Pages: 13 - 13

14. Abatacept/methotrexate

    Case report 21 April 2018 Pages: 14 - 14

15. Acetarsol

    Case report 21 April 2018 Pages: 15 - 15

16. Aciclovir/foscarnet

    Case report 21 April 2018 Pages: 16 - 16

17. Adalimumab

    Case report 21 April 2018 Pages: 17 - 17

18. Adalimumab

    Case report 21 April 2018 Pages: 18 - 18

19. Adalimumab

    Case report 21 April 2018 Pages: 19 - 19

20. Adalimumab/etanercept/infliximab

    Case report 21 April 2018 Pages: 20 - 20

21. Adalimumab/etanercept/infliximab

    Case report 21 April 2018 Pages: 21 - 21

22. Adalimumab/etanercept/infliximab

    Case report 21 April 2018 Pages: 22 - 22

23. Adenosine

    Case report 21 April 2018 Pages: 23 - 23

24. Alendronic acid

    Case report 21 April 2018 Pages: 24 - 24

25. Alirocumab/evolocumab

    Case report 21 April 2018 Pages: 25 - 25

26. Allopurinol/fluorouracil/folinic acid/oxaliplatin

    Case report 21 April 2018 Pages: 26 - 26

27. Aloin/atropine/cathine/diazepam/liothyronine

    Case report 21 April 2018 Pages: 27 - 27

28. Alteplase

    Case report 21 April 2018 Pages: 28 - 28

29. Alteplase

    Case report 21 April 2018 Pages: 29 - 29

30. Ambrisentan/beraprost/bosentan

    Case report 21 April 2018 Pages: 30 - 30

31. Amiodarone

    Case report 21 April 2018 Pages: 31 - 31

32. Amoxicillin

    Case report 21 April 2018 Pages: 32 - 32

33. Amoxicillin/aspirin/carbamazepine

    Case report 21 April 2018 Pages: 33 - 33

34. Amphotericin B liposomal

    Case report 21 April 2018 Pages: 34 - 34

35. Anti-digoxin-polyclonal-antibody/digoxin

    Case report 21 April 2018 Pages: 35 - 35

36. Antiepileptic drugs

    Case report 21 April 2018 Pages: 36 - 36

37. Antineoplastics

    Case report 21 April 2018 Pages: 37 - 37

38. Antineoplastics

    Case report 21 April 2018 Pages: 38 - 38

39. Antineoplastics

    Case report 21 April 2018 Pages: 39 - 39

40. Antineoplastics

    Case report 21 April 2018 Pages: 40 - 40

41. Antineoplastics

    Case report 21 April 2018 Pages: 41 - 41

42. Antineoplastics

    Case report 21 April 2018 Pages: 42 - 42

43. Antineoplastics and pegfilgrastim

    Case report 21 April 2018 Pages: 43 - 43

44. Antithymocyte globulin/hydrocortisone/methylprednisolone

    Case report 21 April 2018 Pages: 44 - 44

45. Antivenin-naja

    Case report 21 April 2018 Pages: 45 - 45

46. Antiviral/immunosuppressants

    Case report 21 April 2018 Pages: 46 - 46

47. Antivirals

    Case report 21 April 2018 Pages: 47 - 47

48. Antivirals

    Case report 21 April 2018 Pages: 48 - 48

49. Antivirals

    Case report 21 April 2018 Pages: 49 - 49

50. Apixaban/dabigatran etexilate/rivaroxaban

    Case report 21 April 2018 Pages: 50 - 50